TL;DR — Senescent cells accumulate and secrete SASPSenescence-Associated Secretory Phenotype — the inflammatory cocktail of cytokines, proteases, and growth factors secreted by senescent (zombie) cells. Full glossary → factors that damage neighbors. SenolyticsCompounds that selectively destroy senescent (zombie) cells that accumulate with age and secrete inflammatory signals. Full glossary → remain experimental; NAD+ support, exercise, and sleep are available now. Track recovery time and inflammation — not just chronological age.
What this hallmark means
When cells hit replicative or damage limits, they enter senescence — a permanent growth arrest that is not always harmless. The Senescence-Associated Secretory Phenotype (SASP) releases IL-6, MMPs, and growth factors that spread dysfunction tissue-wide.
| Failure mode | What changes | What you feel |
|---|---|---|
| SASP amplification | Cytokines from few cells affect many | Persistent stiffness, slow healing |
| Immune clearance failure | NK cells miss senescent cells | "Aging" skin, prolonged inflammation |
| NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary →/sirtuin decline | Senescence brakes weaken | Fatigue + metabolic inflexibility |
Hallmark 7 · Cellular senescence
Both a culprit and consequence — driven by genomic damage and inflammation, then accelerates both.
Why this matters for your protocol
Senolytics (dasatinib + quercetin, fisetin) show promise in mice and small human pilots — but Tier B/C for self-directed use. TNiC focuses on evidence-available layers: reduce new senescence formation (NAD+, NRF2) and improve immune clearance (exercise, sleep).
Intervention hierarchy (evidence-weighted):
- Exercise — best evidence for immune-mediated senescent cell clearance
- NAD+ restoration — supports sirtuin-mediated senescence brakes
- Anti-inflammatory NRF2A protein that turns on 200+ antioxidant and detox genes when activated. Full glossary → stack — reduces SASP amplification environment
- Senolytics — physician-supervised trials only; not DIY
Baker et al. — senescent cell clearance extends healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → in mice. Human senolytic trials ongoing; NAD+ precursors show senescence marker improvements in some cohorts — Tier B for senescence-specific claims.
Practical intervention map
| Lever | Mechanism | Evidence | TNiC resource |
|---|---|---|---|
| Zone 2 + resistance | Immune clearance, SASP reduction | Tier A/B | Exercise |
| NMN | NAD+ → SIRT1 senescence modulation | Tier B (senescence) | NMN |
| NRF2 triad | ↓ SASP-inflammatory environment | Tier A (inflammation) | NRF2 Triad |
| Senolytics | Apoptosis of senescent cells | Tier B/C | Physician only |
← Swipe for more columns →
Your 90-day senescence-focused protocol
Weeks 1–8: Exercise foundation — 150 min Zone 2 + 2× resistance. Log recovery time after hard sessions.
Weeks 9–16: Add NMN 250 mg if NAD+ low or age 55+. Do not start senolytics without trial enrollment or physician protocol.
Weeks 17–24: Layer NRF2 triad if hs-CRP remains elevated — SASP is inflammatory.
Decision point at week 12: Recovery time ↓ and CRP improved → continue. Flat → audit training load and sleep.
Senescence strategy selector
hs-CRP above 1.0 OR recovery time worsening over 6 months?
node | Considering senolytics from internet protocols?
redflag | STOP — senolytics require physician oversight; drug interactions significant
NRF2 triad + exercise emphasis for 12 weeks
node | NAD+ below 80 and age 50+?
NMN 250 mg + exercise maintenance
Lifestyle-only phase 12 weeks → reassess
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
What to measure
| Signal | Type | Frequency | Success looks like |
|---|---|---|---|
| hs-CRP | Lab | 12 wk, quarterly | <1.0 mg/L (SASP proxy) |
| Recovery after hard training | Subjective hours | Per session | ↓20% time to baseline |
| Skin texture / bruising | Subjective | Monthly | Stable or improved |
| NAD+ index | Lab | 12 wk | 80+ if on NMN |
← Swipe for more columns →
hs-CRP (mg/L)
1.8
Hard session recovery
72 hrs
Morning stiffness
7/10
hs-CRP (mg/L)
<1.0
Hard session recovery
48 hrs
Morning stiffness
4/10
Red flags — when to pause or escalate
Stop and consult before intensifying
- Self-directed senolytic protocols — D+Q and fisetin have drug interaction and cytopenia risks
- Unexplained weight loss + elevated CRP — malignancy workup before longevity stacks
- Frailty or falls — aggressive exercise without PT guidance can worsen outcomes
Synergies worth knowing
| Stack | Covers | Best for |
|---|---|---|
| NAD+ Mito Stack | NAD+ + biogenesis | Energy + senescence brakes |
| NRF2 Triad | SASP inflammatory milieu | Elevated CRP |
| Exercise + sleep | Clearance + repair | Everyone — foundation |
Build senescence-aware stack
Prioritize inflammation + mito coverage — senescence follows.
Open Stack ArchitectPersonal results template
My cellular senescence log
| Date | Week | hs-CRP | Recovery (hrs) | Stiffness (1–10) | Training load | NAD+ | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | — | — | — | — | — | Endpoint |
| YYYY-MM-DD | 24 | — | — | — | — | — | Review |
← Swipe for more columns →
Personal response criteria: - Meaningful: CRP ↓30% + recovery time ↓20% - Plateau: Flat at week 12 → training periodization audit - Adverse: CRP spike or new bruising → physician consult
Further reading
- López-Otín et al. Cell 2023 — senescence as a core hallmark (PMID 36599349)
- Kirkland & Tchkonia — Senolytics review
- SASP literature — IL-6/MMP signaling in aging tissue
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.